<DOC>
	<DOC>NCT03005340</DOC>
	<brief_summary>Randomized, open-label, single-dose, three-treatment, six-sequence, three-way crossover study to evaluate the safety and pharmacokinetic characteristics after coadministration of C1-R215 and C2-R215 compared to the administration of C1-R215 and C2-R215 independently in healthy male volunteers</brief_summary>
	<brief_title>A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Healthy male between 19 and 45 BW is above 50kg and BMI is between 18.5 and 30.0 Subject who agreed and signed on informed consent form prior to the study participation Presence or history of clinically significant disease Treatment history of any drug which might affect IP within 10days History of other study drugs within 12weeks</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>